• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Response to: Atezolizumab plus bevacizumab in unresectable HCC: insights from the AMETHISTA trial interim analysis.

作者信息

Rimassa L, Astolfi C, Piscaglia F

机构信息

Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.

Roche S.p.A., Monza, Italy.

出版信息

ESMO Open. 2025 Apr;10(4):104547. doi: 10.1016/j.esmoop.2025.104547. Epub 2025 Mar 31.

DOI:10.1016/j.esmoop.2025.104547
PMID:40168946
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11999198/
Abstract
摘要

相似文献

1
Response to: Atezolizumab plus bevacizumab in unresectable HCC: insights from the AMETHISTA trial interim analysis.回应：阿替利珠单抗联合贝伐单抗治疗不可切除肝细胞癌：来自AMETHISTA试验中期分析的见解
ESMO Open. 2025 Apr;10(4):104547. doi: 10.1016/j.esmoop.2025.104547. Epub 2025 Mar 31.
2
Atezolizumab plus bevacizumab as first-line treatment of unresectable hepatocellular carcinoma: interim analysis results from the phase IIIb AMETHISTA trial.阿替利珠单抗联合贝伐单抗作为不可切除肝细胞癌的一线治疗：IIIb期AMETHISTA试验的中期分析结果
ESMO Open. 2025 Feb;10(2):104110. doi: 10.1016/j.esmoop.2024.104110. Epub 2025 Jan 27.
3
Comment on: Atezolizumab plus bevacizumab in unresectable HCC: insights from the AMETHISTA trial interim analysis.评论：阿替利珠单抗联合贝伐单抗治疗不可切除的肝细胞癌：来自AMETHISTA试验中期分析的见解
ESMO Open. 2025 Apr;10(4):104546. doi: 10.1016/j.esmoop.2025.104546. Epub 2025 Apr 4.
4
Low Baseline CXCL9 Predicts Early Progressive Disease in Unresectable HCC with Atezolizumab Plus Bevacizumab Treatment.低基线CXCL9可预测阿替利珠单抗联合贝伐单抗治疗不可切除肝癌的早期疾病进展
Liver Cancer. 2022 Oct 31;12(2):156-170. doi: 10.1159/000527759. eCollection 2023 Jun.
5
Atezolizumab plus Bevacizumab versus Sorafenib for Unresectable Hepatocellular Carcinoma: Results from Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial.阿替利珠单抗联合贝伐单抗对比索拉非尼治疗不可切除肝细胞癌：IMbrave150随机临床试验中老年人的结果
Liver Cancer. 2022 Jul 13;11(6):558-571. doi: 10.1159/000525671. eCollection 2022 Dec.
6
Depth and Duration of Response Are Associated with Survival in Patients with Unresectable Hepatocellular Carcinoma: Exploratory Analyses of IMbrave150.不可切除肝细胞癌患者的缓解深度和持续时间与生存相关：IMbrave150探索性分析
Liver Cancer. 2025 Mar 3:1-16. doi: 10.1159/000544981.
7
Cost-effectiveness of atezolizumab plus bevacizumab versus sorafenib as first-line therapy in unresectable hepatocellular carcinoma in the US and Chinese setting: a modelling comparison study.在美国和中国背景下，阿替利珠单抗联合贝伐单抗与索拉非尼作为不可切除肝细胞癌一线治疗的成本效益：一项建模比较研究。
BMJ Open. 2025 Mar 6;15(3):e094804. doi: 10.1136/bmjopen-2024-094804.
8
Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82).评估端粒酶衍生的 CD4 Th1 诱导性癌症疫苗联合 atezolizumab 加 bevacizumab 在不可切除肝细胞癌中的应用价值：一项随机非对照 II 期研究（TERTIO-PRODIGE 82）。
BMC Cancer. 2023 Jul 29;23(1):710. doi: 10.1186/s12885-023-11065-0.
9
Achievement of Complete Response and Drug-Free Status by Atezolizumab plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Proof-Of-Concept Study.阿替利珠单抗联合贝伐单抗加或不加根治性转化治疗经动脉化疗栓塞不适合的中期肝细胞癌患者实现完全缓解和无药状态：一项多中心概念验证研究
Liver Cancer. 2023 Feb 7;12(4):321-338. doi: 10.1159/000529574. eCollection 2023 Sep.
10
Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review.阿替利珠单抗联合贝伐单抗对比索拉非尼或单用阿替利珠单抗治疗不可切除肝细胞癌的系统评价
World J Gastrointest Oncol. 2021 Nov 15;13(11):1813-1832. doi: 10.4251/wjgo.v13.i11.1813.

本文引用的文献

1
Comment on: Atezolizumab plus bevacizumab in unresectable HCC: insights from the AMETHISTA trial interim analysis.评论：阿替利珠单抗联合贝伐单抗治疗不可切除的肝细胞癌：来自AMETHISTA试验中期分析的见解
ESMO Open. 2025 Apr;10(4):104546. doi: 10.1016/j.esmoop.2025.104546. Epub 2025 Apr 4.
2
Atezolizumab plus bevacizumab as first-line treatment of unresectable hepatocellular carcinoma: interim analysis results from the phase IIIb AMETHISTA trial.阿替利珠单抗联合贝伐单抗作为不可切除肝细胞癌的一线治疗：IIIb期AMETHISTA试验的中期分析结果
ESMO Open. 2025 Feb;10(2):104110. doi: 10.1016/j.esmoop.2024.104110. Epub 2025 Jan 27.
3
Incidence and Predictors of Esophagogastric Varices Bleeding in Patients with Hepatocellular Carcinoma in Lenvatinib.乐伐替尼治疗肝细胞癌患者食管胃静脉曲张出血的发生率及预测因素
Liver Cancer. 2023 Sep 14;13(2):215-226. doi: 10.1159/000534127. eCollection 2024 Apr.
4
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.多学会专家组关于新的脂肪肝疾病命名的德尔菲共识声明。
J Hepatol. 2023 Dec;79(6):1542-1556. doi: 10.1016/j.jhep.2023.06.003. Epub 2023 Jun 24.
5
Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population.阿替利珠单抗联合贝伐单抗与乐伐替尼治疗不可切除肝细胞癌：一项全球大型真实世界研究。
Eur J Cancer. 2023 Feb;180:9-20. doi: 10.1016/j.ejca.2022.11.017. Epub 2022 Nov 25.
6
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study.阿替利珠单抗联合贝伐珠单抗治疗伴有 A 级和 B 级肝硬化的肝细胞癌患者的安全性和耐受性的初步证据：一项真实世界研究。
Hepatology. 2022 Oct;76(4):1000-1012. doi: 10.1002/hep.32468. Epub 2022 Apr 8.